VTRS
Viatris IncPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free Cash Flow excluding transaction-related and restructuring-related costs non-GAAP | $459M | Three Months Ended March 31, 2026 | — |
| New product revenues | $71M | Three Months Ended March 31, 2026 | — |
| adjusted EBIT non-GAAP | $1B | Q1 2026 call | — |
| adjusted EPS non-GAAP | $59 | Q1 2026 call | — |
| adjusted gross margin non-GAAP | 56% | Q1 2026 call | — |
| capital returned to shareholders through dividend | $140M | Q1 2026 call | — |
| developed markets net sales growth | 1% | Q1 2026 call | — |
| Europe net sales growth | -1% | Q1 2026 call | — |
| free cash flow non-GAAP | $348M | Q1 2026 call | — |
| free cash flow excluding transaction and restructuring-related costs and taxes non-GAAP | $459M | Q1 2026 call | — |
| Greater China net sales growth | 18% | Q1 2026 call | — |
| JANZ net sales growth | -2% | Q1 2026 call | — |
| North America net sales growth | 3% | Q1 2026 call | — |
| operational revenue growth | 3% | Q1 2026 call | — |
| percentage of patients not adequately treated with maximum approved dose of Creon | 76% | Q1 2026 call | — |
| Phase III enrollment rate for Celadogrel | 1,200 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTRS
this stock
Viatris Inc
|
$20.18B | +35.1% | -3.0% | — | 4.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.48B | +5.5% | — | — | 0.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$49.13B | -0.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.62B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTRS | +0.1% | +1.7% | +28.9% | +5.0% | +35.1% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -1.1% | +1.9% | +18.8% | +4.0% | +24.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.